GoogleTwitterFacebook

Phase 1 Clinical Trial of Human Hookworm Vaccine Successfully Completed

Wednesday, September 3, 2014

The Sabin Vaccine Institute (Sabin) today announced that its product development partnership (Sabin PDP) successfully completed a Phase 1 clinical trial in Brazil of Na-GST-1/Alhydrogel®, a vaccine candidate for human hookworm, one of the most pervasive neglected tropical diseases (NTDs) affecting the world’s poor. The Sabin PDP is based at Sabin Vaccine Institute and Texas Children’s Hospital Center for Vaccine Development at Baylor College of Medicine in Houston, Texas. …read the whole press release here

EU Flag
This project has received funding from the European Union’s Seventh Framework Programme for research,
technological development and demonstration under grant agreement no 602843.
Copyright © HOOKVAC 2014. All rights reserved.